TEST:

Oncomine™ BCR IGH-SR Assay

All patients received Rituximab based chemotherapy(R-CHOP[n=31],R-THPCOP[n=13], R-CVP[n=2])... We were able to classify newly diagnosed DLBCL patients into BCR-Low and -High diversity groups using BCR-IgH repertoire analysis, suggesting that classification by BCR-IgH diversity may be a factor to stratify poorprognosis populations such as newly diagnosed DLBCL, especially in IPI-high risk cases.

There is no abstract associated with this presentation.

In post-treatment samples (n = 40), no differences were observed in any clonal/lineage derived metrics between CPR (n = 22) and non-CPR tumors (n = 18). Conclusions Our results support the association between an uneven and less diverse distribution of B cell clones and lineages proportions at diagnosis with complete pathological response after neoadjuvant CI.

(2021) Early changes in the circulating T cells are associated with clinical outcomes after PD‑L1 blockade by durvalumab in advanced NSCLC patients...Journal of Immunotherapy and Precision Oncology. 2 (4): 137–143.

"Here, we performed TCR sequencing in patients from the phase 2 trial SAKK 16/14 undergoing neoadjuvant chemotherapy with three cycles of cisplatin/docetaxel followed by treatment with the PD-L1 antibody durvalumab. In contrast, TMB was not associated with EFS, MPR or nodal clearance (p=0.91, p=0.47, p=0.52). Conclusion Our results show that TCR repertoire measured in peripheral blood samples and tumor tissue may provide a useful tool for predicting risk of recurrence after neoadjuvant sequential chemo-immunotherapy with durvalumab in patients with resectable stage IIIA(N2) NSCLC."